{"id":"NCT03255226","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","officialTitle":"A Multicenter, Open-labeled, Dose-defining Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-07","primaryCompletion":"2021-07-11","completion":"2021-07-15","firstPosted":"2017-08-21","resultsPosted":"2024-08-23","lastUpdate":"2024-08-23"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload"],"interventions":[{"type":"DRUG","name":"Tolvaptan","otherNames":[]}],"arms":[{"label":"Tolvaptan","type":"EXPERIMENTAL"}],"summary":"To determine the efficacy, safety, and dose and regimen of tolvaptan in pediatric CHF patients with volume overload","primaryOutcome":{"measure":"Percentages of Subjects Whose Was Decreased by 1.7% or More Body Weight From Baseline","timeFrame":"Day after Day 3 at evaluation dose","effectByArm":[{"arm":"Tolvaptan","deltaMin":22.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":60},"commonTop":["Thirst","Anaemia","Constipation","Dry mouth","Vomitng"]}}